Author

S. Nambulli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Biochemistry· 1 Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 7 Organism:human· 3 Assay:proteomics· 3 Organism:non-human primate· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

W. P. Duprex· 8 shared L. J. Rennick· 5 shared D. S. Reed· 4 shared N. Tilston-Lunel· 3 shared W. B. Klimstra· 3 shared Y. Shi· 3 shared Y. Xiang· 3 shared Z. Sang· 3 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

W. P. Duprex

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

No evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret model.

D. S. Reed, A. McElroy, D. Barbeau, C. McMillen, N. Tilston-Lunel, S. Nambulli, E. Cottle, T. Gilliland, H. Rannulu, J. Lundy, E. Olsen, K. O'Malley, M. Xia, A. Hartman, T. Luke, , P. Duprex

This study tests if polyclonal SARS-CoV-2 antibodies enhance disease in ferrets, finding no significant differences in symptoms or viral shedding between antibody-treated and control groups.

bioRxiv · Aug 19, 2023 · PreprintMicrobiology

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry

A. J. Guseman, L. J. Rennick, S. Nambulli, C. N. Roy, D. Martinez, D. T. Yang, F. Bhinderwhala, S. Vergara, R. S. Baric, Z. Ambrose, W. P. Duprex, A. M. Gronenborn

This study shows that BOA, a lectin, binds to SARS-CoV-2 Spike glycans and inhibits viral entry at nanomolar concentrations, effective against variants of concern.

bioRxiv · Dec 22, 2022 · PreprintBiochemistry

Super-immunity by broadly protective nanobodies to sarbecoviruses

Y. Xiang, W. Huang, H. Liu, Z. Sang, S. Nambulli, J. Tubiana, K. L. Williams, P. Duprex, D. Schneidman-Duhovny, I. A. Wilson, D. J. Taylor, Y. Shi

The paper isolates and characterizes ultrahigh-affinity nanobodies from a camelid immunized with SARS-CoV-2 RBD, showing broad sarbecovirus neutralization and structural insights.

bioRxiv · Dec 26, 2021 · PreprintMicrobiology

Sustained replication of synthetic canine distemper virus defective genomes in vitro and in vivo

N. Tilston-Lunel, S. R. Welch, S. Nambulli, R. D. de Vries, G. Ho, D. Wentworth, R. S. Shabman, S. T. Nichol, C. F. Spiropoulou, R. L. de Swart, L. J. Rennick, W. P. Duprex

This paper generates and characterizes defective interfering genomes of canine distemper virus, showing their sustained replication in vivo and potential as therapeutic agents.

bioRxiv · Jun 11, 2021Microbiology

Deletion disrupts a conserved antibody epitope in a SARS-CoV-2 variant of concern

L. L. Rennick, L. R. Robinson-McCarthy, S. Nambulli, W. P. Duprex, K. R. McCarthy

The paper identifies a SARS-CoV-2 variant with a deletion in the RBD that disrupts a conserved antibody epitope across sarbecoviruses.

bioRxiv · Mar 5, 2021 · PreprintMicrobiology

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses

S. Nambulli, Y. Xiang, N. L. Tilston-Lunel, L. J. Rennick, Z. Sang, W. B. Klimstra, D. S. Reed, N. A. Crossland, Y. Shi, P. W. Duprex

bioRxiv · Feb 23, 2021Microbiology

Bifurcated monocyte states are predictive of mortality in severe COVID-19

A. R. Cillo, A. Somasundaram, F. Shan, C. Cardello, C. J. Workman, G. D. Kitsios, A. Ruffin, S. Kunning, C. Lampenfeld, S. Onkar, S. Grebinowski, G. Deshmukh, B. Methe, C. Liu, S. Nambulli, , D. A. Vignali

The paper identifies bifurcated monocyte states in severe COVID-19 patients that predict mortality, with distinct cytokine and interferon gene modules associated with survival or death.

bioRxiv · Feb 10, 2021 · PreprintImmunology

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

K. R. McCarthy, L. J. Rennick, S. Nambulli, L. R. Robinson-McCarthy, W. G. Bain, G. Haidar, W. P. Duprex

The paper identifies recurrent deletions in the SARS-CoV-2 spike glycoprotein that drive antibody escape by altering epitopes and accelerating antigenic evolution.

bioRxiv · Nov 19, 2020Microbiology

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2

Y. Xiang, S. Nambulli, Z. Xiao, H. Liu, Z. Sang, W. P. Duprex, D. Schneidman-Duhovny, C. Zhang, Y. Shi

This paper identifies potent SARS-CoV-2 neutralizing nanobodies, develops multivalent cocktails with high neutralization potency, and highlights their therapeutic potential.

bioRxiv · Aug 24, 2020Bioengineering

SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts

A. L. Hartman, S. Nambulli, C. M. McMillen, A. G. White, N. Tilston-Lunel, J. R. Albe, E. L. Cottle, M. D. Dunn, L. J. Frye, T. H. Gilliland, E. L. Olsen, K. J. O'Malley, M. M. Schwarz, J. A. Tomko, R. C. Walker, , W. P. Duprex

bioRxiv · Jun 20, 2020Microbiology

SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients

W. B. Klimstra, N. L. Tilston-Lunel, S. Nambulli, J. Boslett, C. M. McMillen, T. Gilliland, M. D. Dunn, C. Sun, S. E. Wheeler, A. Wells, A. L. Hartman, A. K. McElroy, D. S. Reed, L. J. Rennick, W. P. Duprex

The paper investigates SARS-CoV-2 growth, furin-cleavage-site adaptation, and neutralization using serum from hospitalized COVID-19 patients, finding neutralizing antibody titers are comparable regardless of furin cleavage signal integrity.

bioRxiv · Jun 19, 2020Microbiology